TABLE 2

Postprandial incretin responses related to infusion type

T1D− patientsT1D+ patientsControl subjectsP between groups
GIP
 GLP-15.13 ± 0.6**4.13 ± 0.45**6.04 ± 0.5**0.07
 Saline9.28 ± 1.07.48 ± 0.410.20 ± 0.90.08
 Ex9-398.85 ± 1.07.15 ± 0.79.12 ± 0.70.2
GLP-1
 GLP-129.60 ± 4.1**30.30 ± 2.0**33.76 ± 1.9**0.5
 Saline5.20 ± 0.55.32 ± 0.66.16 ± 0.60.5
 Ex9-397.00 ± 0.5**7.56 ± 0.9**8.29 ± 1.1*0.6
  • Data are mean ± SEM. Total integrated AUC (TAUC; 0–180 min) of total GLP-1 and iGIP (nM × min) during infusion with GLP-1, saline, or Ex9-39 in type 1 diabetic patients without (−) and with (+) residual β-cell function and control subjects.

  • *P ≤ 0.05 vs. saline;

  • **P < 0.01 vs. saline within the same group; no significant differences were found between groups at any infusion type.